Morganella morganii, a non-negligent opportunistic pathogen  by Liu, Hui et al.
International Journal of Infectious Diseases 50 (2016) 10–17Review
Morganella morganii, a non-negligent opportunistic pathogen
Hui Liu 1, Junmin Zhu 1, Qiwen Hu, Xiancai Rao *
Department of Microbiology, College of Basic Medical Sciences, Third Military Medical University, Chongqing 400038, China
A R T I C L E I N F O
Article history:
Received 2 December 2015
Received in revised form 31 March 2016
Accepted 6 July 2016








A B S T R A C T
Morganella morganii belongs to the tribe Proteeae of the Enterobacteriaceae family. This species is
considered as an unusual opportunistic pathogen that mainly causes post-operative wound and urinary
tract infections. However, certain clinical M. morganii isolates present resistance to multiple antibiotics
by carrying various resistant genes (such as blaNDM-1, and qnrD1), thereby posing a serious challenge for
clinical infection control. Moreover, virulence evolution makes M. morganii an important pathogen.
Accumulated data have demonstrated that M. morganii can cause various infections, such as sepsis,
abscess, purple urine bag syndrome, chorioamnionitis, and cellulitis. This bacterium often results in a
high mortality rate in patients with some infections. M. morganii is considered as a non-negligent
opportunistic pathogen because of the increased levels of resistance and virulence. In this review, we
summarized the epidemiology of M. morganii, particularly on its resistance proﬁle and resistant genes, as
well as the disease spectrum and risk factors for its infection.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Morganella morganii is a facultative anaerobic rod Gram-
negative enteric bacterium, which was ﬁrst isolated in 1906 by
Morgan et al. from a pediatric fecal culture.1 The genome size of
M. morganii is about 4,000,000 bp, and the number of its protein-
coding sequences (CDSs) is about 4,000.2 M. morganii was formerly
classiﬁed as Proteus morganii 3 and later assigned to the genus
Morganella, which belongs to the tribe Proteeae of the Enterobacter-
iaceae family on the basis of DNA–DNA hybridization determina-
tions.4 Although members of the tribe Proteeae, including Proteus,
Providencia and Morganella, share homologous genes acquired from
horizontal gene transfer via mobile transposition or conjugative
integration, the overall G+C contents in the genomes of other
Proteeae members range from 39% to 43%, which are lower than that
of the M. morganii (51%); therefore, the G+C contents provides
genetic evidence for distinguishing M. morganii from other species.5
The genus Morganella currently consists of a single species
(M. morganii) with two subspecies, namely, morganii and sibonii.6
Biologically, M. morganii is a motile, non-lactose fermenting
bacterium, which shares with the Proteus members on the capacity* Corresponding author. Department of Microbiology, Third Military Medical
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M. morganii is widely distributed in nature. This bacterium is
commonly found in the environment and intestinal tracts of
humans, mammals, and reptiles as part of the normal ﬂora.7 The
drug resistance of M. morganii is increasing in recent years, and this
resistance is mainly introduced via extra genetic8,9 and mobile
elements.10,11 The infections caused by multidrug-resistant (MDR)
or even the extensively drug-resistant (XDR) M. morganii often
result in clinical treatment failure.12,13 Generally, M. morganii can
produce virulence factors, such as urease, hemolysins, and
lipopolysaccharide (LPS); these virulence factors pose M. morganii
an opportunistic pathogen that mainly causes wound and urinary
tract infections.14–16 Comparative genome analysis revealed several
pathogenicity-related genes, and novel genes carried by M. morganii
genome are not found in the genomes of other Proteeae members,
which may provide important information concerning the virulence
and ﬁtness determinants in M. morganii.17 The disease spectrum of
M. morganii infection varies and is changeable according to its
virulence evolution. This review aims to summarize the epidemiol-
ogy of M. morganii, focus on its resistance proﬁle and resistant
genes, and discuss its disease spectrum and risk factors for infection.
2. Epidemiology of M. morganii
As a member of the family Enterobacteriaceae, M. morganii is
considered as a rare cause of nosocomial infection. Farmer et al.18
classiﬁed the bacteria of Enterobacteriaceae among 11 levelsociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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from the clinical specimen. The relative frequency increases from 0
(not known to occur) to 10 (most common), in which that of M.
morganii is 4, i.e., an opportunistic pathogen that causes rare
infection.
Originally, M. morganii was thought to be a cause of summer
diarrhea and considered to be a very unimportant pathogen.1 This
bacterium was ﬁrst found to be a cause of urinary tract infection in
1939. In the 1970s, M. morganii was shown to be a primary cause of
nosocomial infection in adults and a rare cause of bacteremia.
Adler et al.19 isolated six M. morganii strains from 71 cases of
Proteusbacillus vulgaris bacteremia through investigating the
characteristics of P. vulgaris infections and epidemiology in a
general hospital. In the early 1980s, Tucci and Isenberg reported
13 M. morganii infections scattered over four services and ﬁve
ﬂoors of a hospital; this outbreak was eventually resolved when
strict aseptic techniques, i.e., hand washing, were reinforced.14
Following that incident, M. morganii has been identiﬁed as a
signiﬁcant cause of nosocomial infection, but recognized as an
increasingly important pathogen in recent years. Over a six-year
period (2006–2011), samples from all patients who presented
symptoms of Gram-negative bacterial infections at Changhua
Christian Hospital, Taiwan, were collected. Of the 82,861 samples,
1,219 (1.47%) are positive for M. morganii, which is the ninth
prevalent cause of clinical infections in patients at the said
hospital.17 In addition to Taiwan, other regions including Japan,
USA, and Spain are also the most frequent areas with reported
M. morganii-associated infections. However, the M. morganii-
associated case reports are scattered and often present in
immunocompromised patients.12,20–26 No link exists between
case reported areas and economic status, sanitary condition,
natural environment, and population mobility.
Given the wide distribution of M. morganii in nature,
M. morganii can commendably adapt to the environment for
survival.27 Therefore, M. morganii dissemination may be advanced,
including the mechanisms for M. morganii to cause diseases in both
humans and animals. To assess the carriage of Enterobacteriaceae in
the anterior nares in pig-exposed persons, Fischer et al.28
demonstrated that 66.7% (76/114) of the participants are positive
for Enterobacteriaceae bacteria, with the predominant species of
Proteus mirabilis (14.9%,17/114), followed by Pantoea agglomerans
(11.4%, 13/114), M. morganii (7.9%, 9/114), Citrobacter koseri (7.9%,
9/114), Klebsiella pneumoniae, Escherichia coli, and P. vulgaris (each
7.0%, 8/114). Their studies suggest a possible transmission
pathway between human, and the closely contiguous animal
may exist; further investigation is also needed.
3. Drug resistance and carriage of resistant genes in M.
morganii
The intensive selection pressure of the widely used antibiotics
results in a considerable acceleration of the evolution and spread of
resistant genes in bacteria; moreover, drug resistance has posed a
signiﬁcant challenge for bacterial infection control.29 The bacterial
isolates with MDR, XDR, and pandrug-resistant phenotypes are
increasingly observed.13 Various mechanisms can theoretically
lead to antibiotic resistance; these mechanisms include intrinsic,
acquired, and adaptive resistances.30,31 Intrinsic resistance is the
innate ability of a certain bacterial species to resist the activity of a
particular antimicrobial agent through its inherent structural or
functional characteristics. Such intrinsic insensitivity can be due to
the lacking afﬁnity of the drug for the bacterial target, inaccessi-
bility of the drug into the bacterial cell, or extrusion of the drug by
chromosomally encoded molecules with active exportation
activities. Acquired resistance occurs when a particular bacterial
cell obtains the ability to resist the activity of a particularantimicrobial agent to which it was susceptible previously. This
phenomenon can result from the acquisition of foreign resistance
genes that are horizontally transferred between different strains or
even species via conjugation, or/and from the mutation in certain
genes involved in normal physiological processes and cellular
structures. However, adaptive resistance happens when the
bacterial population is subjected to gradual antibiotic increases;
this resistance is characterized by a rapid emergence of resistance
and reversibility to the normal phenotype when the antibiotic is
removed.32 Adaptive resistance may require epigenetic inheri-
tance and modiﬁcation of gene expression patterns in the
particular bacterial population.
All three kinds of resistances may occur in a particular bacterial
species. M. morganii has intrinsic resistance to oxacillin, ampicillin,
amoxicillin, most of the ﬁrst- and second-generation cephalospor-
ins, macrolides, lincosamides, glycopeptides, fosfomycin, fusidic
acid, and colistin; this pathogen is also normally sensitive to
aztreonam, aminoglycosides, antipseudomonal penicillins, third-
and fourth-generation cephalosporins, carbapenems, quinolones,
trimethoprim/ sulfamethoxazole, and chloramphenicol.33 A
unique biochemical character of M. morganii is that this organism
has the capability for extracellular biosynthesis of crystalline silver
nanoparticles, which was found independent of environmental
changes.34 Three chromosomal gene homologues (silE, silP and silS)
identiﬁed in M. morganii were characterized to be responsible for
the biosynthesis of silver nanoparticles in the presence of Ag+ ions,
as well as the silver-resistant phenotype of the strain.35
Nevertheless, the acquired resistance is increasingly observed in
M. morganii. According to the recent data from the SENTRY
antimicrobial resistance surveillance program, M. morganii ranks
12th among the Gram-negative organisms that cause bloodstream
infections.36 The acquired resistance of M. morganii is commonly
introduced via genetic elements,8–11 however, mutations in certain
genes are also observed. Bacterial genetic elements consist of
prophage, plasmid, transposon, inserted sequence, integron, and so
on. Among them, plasmid, transposon, and integrin, are often
related to antibiotic resistance, and can be transferred between
homogeneous and even heterogeneous bacteria. Antibiotic resis-
tance of M. morganii is mainly mediated by conjugative plasmids
2,8, mutation in certain genes 2,37 and integrons9,38–40. Current
genome sequence and determination with polymerase chain
reaction revealed that the antibiotic-resistant genes carried by
M. morganii are increasing (Table 1). Similar to Enterobacter spp.
and Citrobacter freundii, M. morganii normally has an inducible
AmpC (encodes–lactamase), which confers resistance to those
b-lactam antibiotics (e.g., ampicillin) that induce its strong
synthesis and are labile to its action. Derepression of AmpC,
which is typically caused by mutation at ampD, causes constitutive
b-lactamase hyperproduction and confers resistance to third-
generation cephalosporins. M. morganii shows resistance to
gentamycin.37 Aminoglycoside resistance among Morganella spe-
cies is mediated by various enzyme combinations; the most
frequent of these combinations is the modifying enzyme ANT(2)-I,
which confers resistance to gentamicin, tobramycin, and kanamy-
cin.52 A prevalence of quinolone resistance determinant exists
among M. morganii. The plasmid-mediated quinolone resistant
gene qnrD was ﬁrst reported in 2009 in a human clinical isolate of
Salmonella enteric serovar Kentucky and three Salmonella enteric
serovar Bovismorbiﬁcans isolates from China.53 Mazzariol et al.
(2011) demonstrated the presence of qnrD in isolates of P. mirabilis
and M. morganii; they proposed that qnrD gene is closely linked to
the bacteria of the tribe Proteeae.54 Carbapenems have been used in
clinics as the antibiotics of last resort for the treatment of
nosocomial infections caused by Enterobacteriaceae.55 Resistance
to carbapenems is mostly driven by the production of carbape-
nemases, such as carbapenemase 2 (KPC-2) and New Delhi
Table 1
Detectable drug resistant genes carried by M. morganii
Resistance phenotype Gene Gene name Location Author(cita-
tion)
b-lactams dha-1 b-lactamase DHA-1 Int; P Verdet et al.,40; Mahrouki et al.,41;
dha-5 b-lactamase DHA-5 C Olaitan et al.,2
ampC Penicillin-binding protein AmpC C Sheng et al.,42
ampD Penicillin-binding protein AmpD Sinha et al.,43
ampH Penicillin-binding protein AmpH C Olaitan et al.,2
ampR Penicillin-binding protein AmpR C Chen et al.,17
pse-1 b-lactamase P Olaitan et al.,2
blaNDM-1 New Delhi metallob-lactamase-1 P Olaitan et al.,2
blaOXA-2 OXA-2 b-lactamase Int Power et al.,44
blaOXA-181 Class D b-lactamase OXA-181 P McGann et al.,45
blaOXA-48 Class D b-lactamase OXA-48 Jamal et al.,46
bla(CTX-M) CTX-M b-lactamases C Mahrouki et al.,47
blaKPC-2 Klebsiella pneumonia carbapenemases P Shi et al.,8
blaTEM-1 Class A Extended-Spectrum b-lactamase TEM1 Mahrouki et al.,38
blaTEM-2 Class A extended-spectrumb-lactamase TEM2 Mahrouki et al.,38
blaTEM-24 Class A extended-spectrumb-lactamase TEM24 Mahrouki et al.,38
blaVIM-1 Metallo- b-lactamase VIM-1 Int Tsakris et al.,39
blaP1b Carbenicillinase Int Rojas et al.,9
Aminoglycosides aphA6 Aminoglycoside 30-
phosphotransferase
P Olaitan et al.,2
aadA1 Aminoglycoside
adenylyltransferase
Int Tsakris et al.,39
aadA2 Aminoglycoside
adenylyltransferase




aadB Aminoglycoside adenyltransferase Int Rojas et al.,9
aacA4 Aminoglycoside acetyltransferase Int Power et al.,44
aacA7 Aminoglycoside-acetyltransferase-6-type Ib Int Tsakris et al.,39
rmtB 16S rRNA methylases P Yao et al.,49
Phenicols catA1 Chloramphenicol acetyltransferase C Olaitan et al.,2
catA2 Chloramphenicol aminotransferase C Chen et al.,17
catB3 Chloramphenicol acetyltransferase Int Rojas et al.,9
catB3-like CatB3-like putative acetyltransferase C Chen et al.,17
Macrolides ERY ereA2 Erythromycin esterase P Olaitan et al.,2
mph (A) Macrolide 20-ohosphotransferase P Olaitan et al.,2
Tetracycline tet(A) Tetracycline efﬂux protein C Olaitan et al.,2
tet(D) Tetracycline efﬂux protein C Henriques et al.,50
Trimethoprim dfrA1 Dihydrofolate reductase Int Tsakris et al.,39
dfrA19 Dihydrofolate reductase P Olaitan et al.,2
Fluoroquinolones gyrA(S83R) § DNA gyrase C Olaitan et al.,2
gyrB(S464Y)§ DNA gyrase C Nasri et al.,37
parC(S80I) § Topoisomerase IV C; Int Nasri et al.,37; Mahrouki et al.,38
parE(S458Y)§ Topoisomerase IV C Olaitan et al.,2
qnrA6 Quinolone resistance determinatant A6 P Mahrouki et al.,38
qnrS1 Quinolone resistance determinatant S1 P Mahrouki et al.,41
qnrD Quinolone resistance determinatant D P Seija et al.,12
The others bcr Bicyclomycin resistance gene C Chen et al.,17
ksgA Kasugamycin resistance gene C Chen et al.,17
acrA AcrAB efﬂux pump Ruzin et al.,51
C, chromosome; P, plasmid; Int, integron.
§ Position of the mutations in the protein level.
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2008 in Sweden from a patient who had previously been
hospitalized in New Delhi, India;57 thereafter, a rapid worldwide
dissemination of the said carbapenemase followed.58,59 Multiple
resistant genes (e.g., NDM-1 and qnrD1) carried in a single strain
may cause M. morganii to be an XDR, which has been found in
patient with sepsis.12 Experiences of therapeutic options for the
treatment of invasive infections caused by MDR or XDR of
M. morganii should be accumulated. The ﬁrst blaCTX-M-2-containing
class 1 integron, termed In116, was detected in a plasmid from a
cephalosporin-resistant M. morganii strain, producing CTX-M-2
b-lactamase.44 Other integrons were also identiﬁed in clinical
M. morganii strains, e.g. In3Mor39, sul1-type integron38,40, which
were found to carry various resistant genes (Table 1).
Adaptive resistance has been well established in various
bacterial species, including Escherichia coli, Salmonella enterica,Pseudomonas aeruginosa, and Staphylococcus aureus.31,32 When
these bacteria are exposed to successive steps of increasing
antibiotic concentration, they will rapidly yield populations with
high levels of resistance, and this resistance is highly reversible.
However, no report has focused on adaptive resistance in
M. morganii, and further investigation is suggested.
4. Virulence factors and virulence evolution of M. morganii
Virulence is a primitive character for a pathogen. Genome
sequence revealed that the virulence factors of M. morganii include
ﬁmbrial adhesins, LPS, IgA protease, hemolysins, ureases, and
insecticidal and apoptotic toxins, as well as proteins found in
ﬂagella, iron acquisition system, type-III secretion system (T3SS),
and two-component systems (TCSs) (Table 2). Among them,
ﬁmbrial adhesins, ureases, and TCSs play an important role in
Table 2
Virulence factors of M. morganii
Category Genes
Fimbrial adhesins Three MR/P(mannose-resistant/Proteus-like ﬁmbria) operons, 13 mrpJ paralogous, one ﬁmbrial chaperone, two
UCA(uroepithelial cell adhesin) operons, one PMF(P. mirabilis ﬁmbria) operon, and two other operons; six putative type IV pili
genes hofCB and ppdABCD; two putative trimeric auto transporter secretion genes MM2011 and MM2042
Motility/ﬂagellum-related cheA, cheW, cheD, tap, cheR, cheB, cheY, cheZ, umoABCD, rssBA, rcsBCD
T3SS Type III secretion system needle complex (20 genes), and effectors, ipaCBD operon
Iron acquisition system hmuSTUV, afuABC, feoAB, ireA, btuCD, btuB, and yfeDCBA, 18 other related genes (fecR, ABC transporters, TonB-dep. receptors)
IgA protease zapABCD
Toxin hmpBA, tccB, tccA, tcdB2, xptA1, xptC1, tcdA4, tcaC, tccB3, and tcaC
rtxA, xaxAB, intimin/invasion, HlyD toxin secretion, toxin transporter
Two-component systems 19 potential TCSs were identiﬁed. qseBC, yedWV, BarA/UhpA, phoP/phoQ.
LPS and the cell capsule wzzE, rffC, rffA, wzxE, pagP, arnT, msbA, lpxK, kdsB, kdsC, fepE/wzz, htrB/waaM, rfaD/waaD, rfaF/waaF, rfaC/waaC, wabH, wabG,
waaQ/rfaQ, waaA, waaE, coaD, rfaL, hldE/rfaE, lpxD, lpxA, lpxB, msbB, kdsA, rfaB, lpxH, pgi, galU, lpxC, gale, wecA, rffE, wecC, rffG, rffH,
rffT, wzyE, rffMrcsB, rcsC, rcsD and rcsF.
Ureases ureABCEFGD
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colonization, adhesion is the ﬁrst step in which a pathogen
interacts with the host. Fimbrial adhesins help in bioﬁlm formation
and M. morganii colonization. With the exception of the genes that
encode two LysR family transcriptional regulators, the organiza-
tion of ﬂagellar genes in M. morganii is similar to that of
P. mirabilis.2 Rapid urea hydrolysis is a prominent phenotype of
Proteeae organisms.6 The non-inducible urease gene cluster
consisting of ureABCEFGD was detected in M. morganii. However,
this gene cluster lacks the ureR regulatory gene that was detected
in P. mirabilis HI4320 and Providen ciarettgeri DSM1131.2 Urease
production serves as a ﬁtness factor that facilitates bacterial
growth and bioﬁlm formation during urinary tract infections,
which may explain why M. morganii mainly causes the urinary
tract infection. Importantly, ureases from M. morganii urease gene
cluster are required for bacterial virulence.60
A most important achievement of bacteria is its ability to adapt
to the changing environmental conditions. Competition with other
microorganisms has led a plethora of bacterial mechanisms to
adapt to a wide variety of stress conditions rapidly. Standard
virulence evolution theory assumes that virulence factors are
maintained because they aid bacterial colonization, thereby
increasing bacterial growth within and/or transmission between
hosts.49 M. morganii has developed several systems to cope with
the varied environment, such as TCSs, which constitute a most
sensible and efﬁcient regulatory mechanism in bacteria. TCSs
generally contain paired sensor kinase and response regulator
proteins and form the primary apparatus for sensing and
responding to environmental cues in bacteria. Nineteen potential
TCSs were identiﬁed in M. morganii.17 These TCSs play important
roles in the virulence and ﬁtness of M. morganii. Nevertheless,
pmrA/pmrB was not detected in the genome of M. morganii and
other Proteeae members.2 The pathogenic genes allow the usage of
computation approaches to identify potential drug targets, such as
the conserved proteins found in common pathogens. The presence
of eut (which includes pduST) and cob-cbi operons in M. morganii
but not in other Proteeae genomes studied may explain why
M. morganii is more frequently associated with nosocomial
bacterial infections.17 ArnT mediates lipid A modiﬁcation. Two
copies of the arnT gene were detected in the genome of M. morganii
and other Proteeae members, whereas non-Proteeae bacteria have
only one copy.2
ICEPm1, a highly modular and highly conserved pathogenicity
island (PAI), is commonly found in M. morganii strains. This 94-kb
PAI (ICEPm1) encodes 91 open reading frames (ORFs) with a G+C
content of 44.84%, which differs substantially from that of the
M. morganii genome (51%).61 ICEPm1 carries several genes involved
in DNA mobility, characteristic for PAIs, including an integrase, sixtransposases, and ﬁve plasmid-transfer related proteins. An
important core segment found in ICEPm1(PMI2569 to PMI2592)
shows homology to a type-IV secretion system that is important
for DNA transfer of ICEHin1056.62 A T3SS, which comprises gene
products MM0224 through MM0247 and has a low G+C content
(43.7%), resides in a 20.8-kb PAI.17 This PAI encodes 24 ORFs and
shares homologous syntenic blocks with P. mirabilis,63 which
contains all the components needed to assemble a T3SS needle
complex. Sequence comparison between M. morganii KT and the
14 members of the Enterobacteriaceae family, revealed that
459 CDSs found in M. morganii are not found in the other Proteeae
species studied, and 295 CDSs found in M. morganii are not found in
any of the 14 Enterobacteriaceae genomes studied. The genes
speciﬁc to M. morganii include the genes in the eut operon, cob-cbi
operon, eight insecticidal toxin genes, nine T3SS genes, and
17 copies of the IS4 family transposase gene.17 However, the
evidence that M. morganii shares features with other non-Proteeae
enterobacteria suggests that horizontal gene transfer has occurred
between M. morganii and other intestinal bacteria.
5. Disease spectrum and risk factors for M. morganii infection
M. morganii is an unusual opportunistic pathogen that is
clinically and often isolated as a cause of nosocomial infection in
adults, speciﬁcally in urinary tract or wound infections. Urinary
tract is the major portal for M. morganii entry, followed by the
hepatobiliary tract, skin and soft tissue, and blood. However,
M. morganii has been recognized an increasingly important
pathogen because of its virulence and increasing drug resistance,
which has resulted in a high mortality rate in some infections. To
date, a total of 136 cases with M. morganii infection have been
reported. The disease spectrum associated with M. morganii
infections is summarized in Table 3. The diseases caused by
M. morganii are diversiﬁed; these diseases include pyelonephritis,
septic shock, urinary tract infection, osteomyelitis, peritonitis,
abscess, purple urine bag syndrome, joint effusions, meningitis,
sepsis, necrotizing fasciitis, pericarditis, pneumonia, aortic aneu-
rysm, hemorrhagic bullae, bacteremia, septic arthritis,
endophthalmitis, Waterhouse–Friderichsen syndrome, Ludwig’s
angina, pancreatitis, gangrenosum, chorioamnionitis, pyomyositis,
ulcer, cellulitis, and wound infection. The mortality of M. morganii
infections remains high in reported cases.22,23,70,76,77,92–94,97,109,124
M. morganii mainly causes sepsis (11.0%, 15/136), abscess (9.6%,
13/136), urinary tract infection (8.1%, 11/136), bacteremia (7.4%,
10/136), purple urine bag syndrome (5.9%, 8/136), chorioamnio-
nitis (5.9%, 8/136), cellulitis (5.9%, 8/136), and wound infection
(5.9%, 8/136). Remarkably, among the M. morganii-associated
sepsis cases, 11 cases are neonates. Maternal chorioamnionitis,
Table 3
Major diseases caused by M. morganii
Diagnosis No. of isolates Author(citation)
Pyelonephritis 6 Nasri et al.,37; Falagas et al.,64.
Septic shock 2 Tan et al.,65; Cornely and Schirmacher,66.
Urinary tract infection 11 Tucci and Isenberg,14; Sakaguchi et al.,15; Sakai et al.,16; Jamal et al.,46; Volpato et al.,67; Ibara et al.,68.
Osteomyelitis 2 Smithson et al.,69; Koyuncu and Ozan,70.
Peritonitis 3 Tsai et al.,26; Atalay et al.,71; Isobe et al.,72.
Abscess 13 Zaid et al.,25; McGann et al.,45; Carruth and Wladis,73; Chen and Lin,74; Chou et al.,75; Osanai et al.,76; Abdalla
et al.,77; Lim et al.,78; Pomeranz et al.,79; Sumioka et al.,80; Huang et al.,81;Vijaya et al.,82;Patil et al.,83.
Purple urine bag syndrome 8 Iglesias et al.,84; Muneoka et al.,85; Matsuo et al.,86.
Joint effusions 1 Sanz et al.,87
Meningitis 5 Mastroianni et al.,20; Milligan and Barenkamp,88; Ndiaye et al.,89; Samonis et al.,90; Isaacs and
Ellis-Pegler,91.
Sepsis 15 Seija et al.,12; Chang et al.,92; Ovalle et al.,93; Kim et al.,94; Golubic-Cepulic et al.,95.
Necrotizing fasciitis 3 Soleimanian et al.,96; Krebs et al.,97; Kohagura et al.,98.
Pericarditis 3 Cho et al.,99; Yang et al.,100; Sica et al.,101.
Pneumonia 5 Falagas et al.,64; Mounir et al.,102; Choi et al.,103; Garcia-Garai et al.,104; Martin et al.,105.
Aortic aneurysm 1 Kwon et al.,106
Haemorrhagic bullae 2 Lee et al.,7; Bagel and Grossman,107.
Bacteraemia 10 Sakai et al.,16; Adler et al.,19; Mahrouki et al.,41; Pappas et al.,108; Ghosh et al.,109.
Septic arthritis 6 Gautam et al.,21; Isaacs and Ellis-Pegler,91.
Endophthalmitis 5 Kuang et al.,110; Christensen et al.,111; Tsanaktsidis et al.,112; Zaninetti et al.,113; Cunningham et al.,114.
Waterhouse-Friderichsen syndrome 1 Tourrel et al.,115
Pancreatitis 1 Yeh et al.,116
Gangrenosum 2 Falagas et al.,64; Del et al.,117.
Chorioamnionitis 8 Rowen and Lopez,24; Sinha et al.,43; Chang et al.,92; Ovalle et al.,93; Johnson and Feingold,118; Carmona
et al.,119; Boussemart et al.,120; Ranu and Valencia,121.
Pyomyositis 1 Arranz-Caso et al.,22
Ulcer 5 Falagas et al.,64; McDermott and Mylotte,122; Lachish et al.,123.
Cellulitis 8 Falagas et al.,64
Wound infection 9 Tucci and Isenberg,14; Falagas et al.,64.
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neonatal sepsis, is the most common antenatal risk.24,43,92,120,121
All reported cases are premature, with antenatal exposure to
ampicillin/amoxicillin being reported in several case-
s.23,24,92,120,121 The above situation could be explained by the
common practice of administering ampicillin and antenatal
steroids to mothers with threatened premature delivery. Routine
intrapartum antibiotic prophylaxis with ampicillin may lead to the
emergence of infections because of resistant Gram-negative
organisms. Antenatal steroids are beneﬁcial in accelerating
maturity of fetal lung and other organ systems; they also have
an established role in the management of women with preterm
rupture of membranes.125 However, the use of these steroids may
increase the risk of infection.126 The use of dexamethasone and
ampicillin in mothers leads to ampicillin resistance of
M. morganii. This pathogen can be spread to babies by vertical
transmission from the mother’s genitourinary tract during
delivery.
As an opportunistic pathogen, several risk factors may be
involved in M. morganii infection. In 1994, McDermott
et al. reported that these risk factors include old age, presence
of concomitant bacteremia, hospitalization, recent surgery, and
concurrent antibiotic use.122 M. morganii can be derived from the
bacterial ﬂora of the oral cavity of animals and cause infections in
humans through bites127,128 or scratch.7 Therefore, some animals
should be considered a potential risk for transmitting M. morganii
to persons, speciﬁcally in immunocompromised hosts. Adminis-
tration of patients infected with M. morganii could be potentially
dangerous and should not be overlooked. Treatment for
M. morganii infections mainly includes antibiotic therapy, debride-
ment, and drainage. Proper use of antibiotics and supportive care
are important in improving cure rate. Antibiotic use is mainly
suggested to be based on the antibiotic sensitivity results
from bacterial cultures and clinical improvement. M. morganii
is characteristically resistant to many b-lactam antibiotics, thus a
third-generation cephalosporin alone or with gentamicin for 10–
14 days is effective in treating M. morganii infections.92 Addition ofan aminoglycoside to a cephalosporin may decrease the potential
resistance to broad-spectrum cephalosporins. M. morganii causing
intracranial infections are noteworthy and warrant continued
monitoring because antibiotic selection for treatment is affected
not only by the organism’s intrinsic susceptibilities but also by the
antibiotic’s ability to penetrate and maintain therapeutic levels.
Treating M. morganii infection in the central nervous system is
usually difﬁcult. For the treatment of a patient infected with XDR
M. morganii harboring NDM-1 and qnrD1, Seija et al. proposed the
use of fosfomycin and double doses of meropenem.12
6. Conclusion and perspective
M. morganii has been recognized as an increasingly important
pathogen. The disease spectrum associated with M. morganii
infections is broad, and the mortality of such infections remains
high in reported cases. Previously, not much attention was given to
this pathogen because of its rarity and low potential for nosocomial
epidemics. Infections with M. morganii are particularly worrisome
epidemiologically because of the organism’s inducible resistance
to b-lactam antibiotics. Although M. morganii is an unusual clinical
opportunistic pathogen, this important pathogen cannot be
neglected. Considering the increased frequency of M. morganii
infection, to develop a rapid detection method and enhance
research on this pathogen are important. The genome sequence of
M. morganii provides important information concerning virulence
and determinants of ﬁtness. Further investigation is needed to
ascertain the pathogenic mechanism of M. morganii and block the
development of Morganella infections. The above suggestions
would help in re-classiﬁcation of M. morganii as a rare pathogen.
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